We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Next-Generation Multiomics Blood-Based Test for Pancreatic Cancer Could Become Powerful Tool for Early Diagnosis and Treatment

By LabMedica International staff writers
Posted on 07 Oct 2021
Print article
Illustration
Illustration

Freenome Holdings, Inc. (South San Francisco, CA, USA) has demonstrated the potential of extending its multiomics approach into other cancers, such as pancreatic cancer, with biomarkers already embedded in the existing platform.

Pancreatic cancer is one of the deadliest cancers, with an overall five-year survival rate of 11%. If detected at an early stage, the five-year survival rate increases to 42%. The only FDA-authorized test for pancreatic cancer is the carbohydrate antigen 19-9 (CA19-9), which is only cleared for monitoring response to therapy.

The retrospective study of 75 participants evaluated whether Freenome's multiomics approach of combining methylation and CA19-9 signals together (as a subset of existing analytes in the platform) detected pancreatic cancer in stages II, III and IV with higher sensitivity than either alone. Across all stages studied, Freenome's approach achieved a sensitivity of 93% at a nominal specificity of 96%. At an identical specificity, the sensitivity of methylation or CA19-9 alone was 74% and 87%, respectively. In stages II, III and IV, the multiomics approach achieved a sensitivity of 82%, 89%, and 100%, respectively.

The new study demonstrates that Freenome's platform can be used to detect pancreatic cancer in addition to colorectal cancer (CRC). Last year, Freenome presented data showing a sensitivity of 94% at a specificity of 94% for early-stage (I/II) CRC using their multiomics platform. Freenome's CRC test is currently undergoing analytical and clinical validation.

"We're demonstrating success in detecting CRC and advanced adenomas in blood. We're now expanding our platform to detect additional cancers," said Mike Nolan, chief executive officer, Freenome. "Our goal is to transform the way cancer of all types is managed by enabling early detection, and this data on pancreatic cancer is an important step in that direction."

"An accurate blood-based test like this could be a powerful tool for early diagnosis and treatment, impacting so many patients," said Randall Brand, M.D., professor of Medicine and Human Genetics at the University of Pittsburgh School of Medicine, and co-author of the study. "We are hoping to further validate the findings through additional studies, which are already underway."

Related Links:
Freenome Holdings, Inc. 

Gold Supplier
Vaginosis Test
VAGINAL PANEL REALTIME PCR KIT
New
Blood Transfusion Safety Test
ABTest Card
New
Hepatitis/HBcAb CLIA Test
DIA.CHEMILUX HBcAb
New
EML4-ALK/KIF5B-ALK Fusion Gene Detection Test
QFusion EML4-ALK and KIF5B-ALK Fusion Gene Detection Test

Print article

Channels

Microbiology

view channel
Image: Trichinella sp. found in muscle tissue (Photo courtesy of McGill University)

Laboratory Features of Trichinellosis and Eosinophilia Threshold Determined

Trichinella nativa is a nematode worm, one of the species of the genus Trichinella, found in arctic and subarctic regions. It is highly pathogenic and has a high resistance to freezing. It is encapsulated,... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.